302 related articles for article (PubMed ID: 22879434)
21. Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations.
Tambaro FP; Wierda WG
Lancet Haematol; 2020 Feb; 7(2):e168-e176. PubMed ID: 32004486
[TBL] [Abstract][Full Text] [Related]
22. [Tumor lysis syndrome].
Hagino T
Gan To Kagaku Ryoho; 2010 Jun; 37(6):984-8. PubMed ID: 20567098
[TBL] [Abstract][Full Text] [Related]
23. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies.
Ribeiro RC; Pui CH
Clin Lymphoma; 2003 Mar; 3(4):225-32. PubMed ID: 12672271
[TBL] [Abstract][Full Text] [Related]
24. A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.
Bose P; Qubaiah O
J Clin Pharm Ther; 2011 Jun; 36(3):299-326. PubMed ID: 21501203
[TBL] [Abstract][Full Text] [Related]
25. Our experience with tumor lysis syndrome treatment.
Sirelkhatim A; Sejnova D; Puskacova J; Subova Z; Kaiserova E
Bratisl Lek Listy; 2008; 109(12):560-3. PubMed ID: 19348378
[TBL] [Abstract][Full Text] [Related]
26. Acute tumor lysis syndrome in solid tumors--a case report and review of the literature.
Baeksgaard L; Sørensen JB
Cancer Chemother Pharmacol; 2003 Mar; 51(3):187-92. PubMed ID: 12655435
[TBL] [Abstract][Full Text] [Related]
27. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
[TBL] [Abstract][Full Text] [Related]
28. Rasburicase for the treatment of tumor lysis in hematological malignancies.
Malaguarnera G; Giordano M; Malaguarnera M
Expert Rev Hematol; 2012 Feb; 5(1):27-38. PubMed ID: 22272702
[TBL] [Abstract][Full Text] [Related]
29. Impact of dialysis requirement on outcomes in tumor lysis syndrome.
Garimella PS; Balakrishnan P; Ammakkanavar NR; Patel S; Patel A; Konstantinidis I; Annapureddy N; Nadkarni GN
Nephrology (Carlton); 2017 Jan; 22(1):85-88. PubMed ID: 27119419
[TBL] [Abstract][Full Text] [Related]
30. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
[TBL] [Abstract][Full Text] [Related]
31. Treatment-naïve spontaneous tumor lysis syndrome in metastatic prostate adenocarcinoma: An unusual suspect.
Ignaszewski M; Kohlitz P
Am J Emerg Med; 2017 Sep; 35(9):1384.e1-1384.e2. PubMed ID: 28587951
[TBL] [Abstract][Full Text] [Related]
32. How we treat tumor lysis syndrome.
Muslimani A; Chisti MM; Wills S; Nadeau L; Zakalik D; Daw H; Huang J; Jaiyesimi I
Oncology (Williston Park); 2011 Apr; 25(4):369-75. PubMed ID: 21618960
[TBL] [Abstract][Full Text] [Related]
33. Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?
Canet E; Cheminant M; Zafrani L; Thieblemont C; Galicier L; Lengline E; Schnell D; Reuter D; Darmon M; Schlemmer B; Azoulay E
Leuk Lymphoma; 2014 Oct; 55(10):2362-7. PubMed ID: 24325633
[TBL] [Abstract][Full Text] [Related]
34. [Recommendations for tumor lysis syndrome management].
Comité Nacional de Hematología, Oncología y Medicina Transfusional
Arch Argent Pediatr; 2020 Apr; 118(2):S59-S63. PubMed ID: 32199069
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies.
Pei Y; Li Y; Liang Y; Xu L; Huang X; Li Y; Tang W; Jiang X
Int J Clin Pharm; 2020 Dec; 42(6):1440-1446. PubMed ID: 32974856
[TBL] [Abstract][Full Text] [Related]
36. Managing tumor lysis syndrome.
Greguska C
JAAPA; 2021 Jan; 34(1):10-13. PubMed ID: 33315730
[TBL] [Abstract][Full Text] [Related]
37. Incidence and pathogenesis of tumor lysis syndrome.
Locatelli F; Rossi F
Contrib Nephrol; 2005; 147():61-68. PubMed ID: 15604606
[TBL] [Abstract][Full Text] [Related]
38. Tumour lysis syndrome: implications for cancer therapy.
Mika D; Ahmad S; Guruvayoorappan C
Asian Pac J Cancer Prev; 2012; 13(8):3555-60. PubMed ID: 23098434
[TBL] [Abstract][Full Text] [Related]
39. Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.
Cheson BD; Heitner Enschede S; Cerri E; Desai M; Potluri J; Lamanna N; Tam C
Oncologist; 2017 Nov; 22(11):1283-1291. PubMed ID: 28851760
[TBL] [Abstract][Full Text] [Related]
40. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
Cortes J; Moore JO; Maziarz RT; Wetzler M; Craig M; Matous J; Luger S; Dey BR; Schiller GJ; Pham D; Abboud CN; Krishnamurthy M; Brown A; Laadem A; Seiter K
J Clin Oncol; 2010 Sep; 28(27):4207-13. PubMed ID: 20713865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
